You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 19, 2025

Investigational Drug Information for Tavapadon


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Tavapadon?

Tavapadon is an investigational drug.

There have been 9 clinical trials for Tavapadon. The most recent clinical trial was a Phase 1 trial, which was initiated on October 27th 2020.

The most common disease conditions in clinical trials are Parkinson Disease, Liver Diseases, and Renal Insufficiency. The leading clinical trial sponsors are Cerevel Therapeutics, LLC and [disabled in preview].

There are eleven US patents protecting this investigational drug and seventy-nine international patents.

Recent Clinical Trials for Tavapadon
TitleSponsorPhase
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's DiseaseCerevel Therapeutics, LLCPhase 1
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult ParticipantsCerevel Therapeutics, LLCPhase 1
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCerevel Therapeutics, LLCPhase 1

See all Tavapadon clinical trials

Clinical Trial Summary for Tavapadon

Top disease conditions for Tavapadon
Top clinical trial sponsors for Tavapadon

See all Tavapadon clinical trials

US Patents for Tavapadon

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tavapadon ⤷  Try for Free Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) ⤷  Try for Free
Tavapadon ⤷  Try for Free Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (New York, NY) ⤷  Try for Free
Tavapadon ⤷  Try for Free Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) ⤷  Try for Free
Tavapadon ⤷  Try for Free 1,5-naphthyridine derivatives and MELK inhibitors containing the same OncoTherapy Science, Inc. (Kanagawa, JP) ⤷  Try for Free
Tavapadon ⤷  Try for Free Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) ⤷  Try for Free
Tavapadon ⤷  Try for Free Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) ⤷  Try for Free
Tavapadon ⤷  Try for Free 1,5-naphthyridine derivatives and MELK inhibitors containing the same OncoTherapy Science, Inc. (Kanagawa, JP) ⤷  Try for Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tavapadon

Drugname Country Document Number Estimated Expiration Related US Patent
Tavapadon Argentina AR096748 2033-06-27 ⤷  Try for Free
Tavapadon Australia AU2014300673 2033-06-27 ⤷  Try for Free
Tavapadon Brazil BR112015030101 2033-06-27 ⤷  Try for Free
Tavapadon Canada CA2916653 2033-06-27 ⤷  Try for Free
Tavapadon Chile CL2015003735 2033-06-27 ⤷  Try for Free
Tavapadon China CN105324376 2033-06-27 ⤷  Try for Free
Tavapadon Costa Rica CR20150634 2033-06-27 ⤷  Try for Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Tavapadon: A Promising Candidate in the Treatment of Parkinson’s Disease

Introduction to Tavapadon

Tavapadon, a novel drug candidate, has been making significant strides in the treatment of Parkinson’s disease (PD), a neurodegenerative disorder affecting over 10 million people worldwide. Developed by Cerevel Therapeutics and recently acquired by AbbVie, tavapadon is poised to revolutionize the management of PD symptoms.

Mechanism of Action

Tavapadon acts as a D1/D5 dopamine receptor partial agonist, targeting specific dopamine receptors in the brain. This mechanism is unique and distinguishes tavapadon from other treatments, making it a first-in-class therapy for PD[3][4].

Clinical Trials: TEMPO Series

The clinical development of tavapadon has been extensive, with several phase 3 trials under the TEMPO series.

TEMPO-1 Trial

The TEMPO-1 trial evaluated tavapadon as a standalone treatment for early-stage PD. This double-blind, randomized, placebo-controlled trial demonstrated the efficacy, safety, and tolerability of tavapadon at two fixed doses over 27 weeks. The results were positive, showing statistically significant improvements in PD symptoms compared to placebo[2][4].

TEMPO-2 Trial

The TEMPO-2 trial assessed tavapadon as a flexible-dose monotherapy in patients with early PD. The trial met its primary endpoint, showing a statistically significant improvement in the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts two and three combined score at week 26. The key secondary endpoint was also met, indicating a clinically meaningful improvement in motor aspects of daily living[1][4].

TEMPO-3 Trial

The TEMPO-3 trial evaluated tavapadon as an adjunctive therapy to levodopa, a common first-line treatment for PD motor symptoms. The trial reinforced tavapadon’s potential as a once-daily treatment, showing positive results in efficacy, safety, and tolerability[2][4].

Safety and Tolerability

Across all TEMPO trials, tavapadon has demonstrated a consistent safety profile. The drug’s tolerability has been favorable, with no significant adverse effects reported that would hinder its potential for regulatory approval[1][2][4].

Regulatory Pathway

With the positive results from the TEMPO trials, AbbVie is on track to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) in 2025. This submission is a crucial step towards making tavapadon available for patients with PD[1][4].

Market Projections

Launch and Revenue

Tavapadon is expected to launch in the US in 2025 and is projected to generate significant market revenue. Initial estimates suggest that the drug could generate USD 1.4 million upon its release, with potential for growth as it penetrates the market[2].

Global Market Forecast

The market for tavapadon is expected to expand significantly over the next decade. A comprehensive report forecasts the market size in seven major markets (the US, EU4 countries, the UK, and Japan) from 2019 to 2032. The projections indicate a substantial increase in market size, driven by extensive research and incremental healthcare spending globally[5].

Competitive Landscape

While tavapadon is poised to be a dominant player, it will face competition from other emerging therapies for PD. The market is expected to be dynamic, with several late-stage therapies set to launch in the near future, which could impact tavapadon’s market share[5].

Long-Term Safety and Tolerability

To further assess the long-term safety and tolerability of tavapadon, AbbVie is conducting an open-label extension trial, TEMPO-4. This trial will provide valuable data on the drug’s long-term efficacy and safety profile, which is crucial for its sustained use in clinical practice[1].

Expert Insights

Primal Kaur, Senior Vice President of Immunology, Neuroscience, Eye Care, and Specialty Development at AbbVie, highlighted the potential of tavapadon: “The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 partial agonist for the treatment of PD. With this data in hand, we look forward to working with regulatory agencies to assess next steps, bringing us one step closer to providing tavapadon for those living with this chronic, debilitating disease”[1][4].

Key Takeaways

  • Mechanism of Action: Tavapadon is a D1/D5 dopamine receptor partial agonist.
  • Clinical Trials: Positive results from TEMPO-1, TEMPO-2, and TEMPO-3 trials.
  • Safety and Tolerability: Consistent safety profile across trials.
  • Regulatory Pathway: NDA submission to FDA expected in 2025.
  • Market Projections: Projected to generate USD 1.4 million upon launch, with significant growth potential.
  • Long-Term Safety: TEMPO-4 trial to assess long-term safety and tolerability.

FAQs

Q: What is the mechanism of action of tavapadon?

A: Tavapadon acts as a D1/D5 dopamine receptor partial agonist, targeting specific dopamine receptors in the brain[3][4].

Q: Which company is developing tavapadon?

A: Tavapadon was developed by Cerevel Therapeutics and is now under the umbrella of AbbVie following its acquisition in August 2024[2][4].

Q: What are the key findings from the TEMPO trials?

A: The TEMPO trials have shown statistically significant improvements in PD symptoms, including motor aspects of daily living, and have demonstrated the safety and tolerability of tavapadon[1][2][4].

Q: When is tavapadon expected to be launched?

A: Tavapadon is expected to launch in the US in 2025, pending FDA approval[2][4].

Q: What is the projected market revenue for tavapadon?

A: Initial estimates suggest that tavapadon could generate USD 1.4 million upon its release, with potential for significant growth over the next decade[2].

Sources

  1. PMLiVE: AbbVie's Parkinson's disease candidate tavapadon shows promise in phase 3 trial.
  2. DelveInsight: Evaluating the Upcoming Drugs for Parkinson's Disease Treatment.
  3. GlobalData: Tavapadon (PF-06649751) in Parkinson's Disease - LOA and Trend Analysis.
  4. World Pharmaceuticals: AbbVie's tavapadon meets primary endpoint in Phase 3 Parkinson's disease trial.
  5. Research and Markets: Tavapadon Market Size, Forecast, and Emerging Insight - 2032.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.